



Lab resource: Stem cell line

Establishment of induced pluripotent stem cell (iPSC) line from an 8-year old female patient with ischemic Moyamoya disease



Marina Cardano^a, Fabio Marsoner^{a,1}, Jacopo Zasso^a, Matteo Marcatili^{a,b,c}, Thodoris Karnavas^{d,2}, Luigi Andrea Lanterna^{e,*}, Luciano Conti^{a,*}

^a Laboratory of Stem Cell Biology, Centre for Integrative Biology-CIBIO, Università degli Studi di Trento, Trento, Italy

^b Department of Health Sciences, Università Degli Studi di Milano, Milan, Italy

^c Department of Mental Health, San Paolo Hospital, Milan, Italy

^d Chromatin Dynamics Unit, San Raffaele University and Research Institute, Milan, Italy

^e Department of Neuroscience and Surgery of the Nervous System, Papa Giovanni XXIII Hospital, Bergamo, Italy

ARTICLE INFO

Article history:

Received 11 October 2016

Accepted 1 November 2016

Available online 5 November 2016

ABSTRACT

Peripheral blood mononuclear cells (PBMCs) were collected from an 8-year old female patient affected by ischemic Moyamoya disease (MMD). Patient's PBMCs were reprogrammed using Sendai virus particles delivering the four Yamanaka factors. The footprint free hiPSC line expressed the major pluripotency markers and exhibited a normal karyotype. Cells were competent to give rise to progeny of differentiated cells belonging to the 3 germ layers. This hiPSC line represents a good tool to *in vitro* model MMD in order to shed light on the cellular and molecular mechanisms responsible for the occurrence of this syndrome.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Resource table.

Name of stem cell line	MMD ISCH#6 iPSC line
Institution	Department of Neuroscience and Surgery of the Nervous System, Papa Giovanni XXIII Hospital, Bergamo, Italy; Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
Person who created resource	Luigi Andrea Lanterna, Luciano Conti
Contact person and email	Luigi Andrea Lanterna, l.lanterna@gmail.com ; Luciano Conti, Luciano.Conti@unitn.it
Date archived/stock date	October 2015
Origin	Peripheral blood mononuclear cells (PBMCs)
Type of resource	Biological reagent: induced pluripotent stem cell (iPSC); derived from a sporadic ischemic Moyamoya disease (MMD) patient
Sub-type	Induced pluripotent stem cells (iPSCs)
Key transcription factors	hOCT4, hSOX2, hc-Myc, hKLF4 (CytoTune™-iPS 2.0 Sendai Reprogramming Kit - Thermo Fisher Scientific)
Authentication	Identity and purity of the cell line was confirmed by the following tests: expression of pluripotency genes by

RT-PCR, western blot and immunofluorescence, expression of SeV specific genome by RT-PCR, chromosome stability by karyotyping, *in vitro* differentiation in the 3 germ-layer derivatives

Link to related literature

/

Information in public databases

/

Ethics

Patient informed consent obtained; Ethics Review Board-competent authority approval was obtained from the Papa Giovanni XXIII Hospital Ethical Board

1. Resource details

Blood sample was collected from an 8-year old female patient with Moyamoya disease (MMD; Papa Giovanni XXIII Hospital, Bergamo, Italy). Patient presented a minor stroke and multiple transient ischemic attacks (TIA) characterized by transient motor deficits of the right hand. The MR showed an infarct in the fronto-parietal region on the left side and multiple small ischemic lesions in the deep and superficial watershed areas of both hemispheres. A computed tomography angiography demonstrated the complete occlusion of the internal carotid artery distal to the origin of the anterior choroidal artery on both sides with the compensatory hypertrophy of the basal lenticulostriate arteries, indicative for MMD. A postoperative digital subtraction angiography was consistent with the diagnosis of MMD.

Purified patient's PBMCs were transduced with Sendai virus particles (Yang et al., 2008–2012), delivering the four Yamanaka factors

* Corresponding authors.

E-mail addresses: fm@uni-bonn.de (F. Marsoner), tk2708@cumc.columbia.edu (T. Karnavas), l.lanterna@gmail.com (L.A. Lanterna), Luciano.Conti@unitn.it (L. Conti).

¹ Current address: Institute of Reconstructive Neurobiology, LIFE and BRAIN Center, University of Bonn, Bonn, Germany.

² Current address: Department of Genetics & Development, Columbia University, Medical Center, New York, USA.




Fig. 1. Characterization of MMD ISCH#6 hiPSC line. **A:** Representative picture of a MMD ISCH#6 hiPSC colony (5 \times) and its karyogram showing a normal diploid 46, XY karyotype with no evident cytogenetic aberrations. Immunophenotypical characterization showing the expression of the pluripotency markers OCT4, Nanog, TRA-1-60, SOX2 (40 \times). **B:** RT-PCR displaying the expression of the pluripotency-associated genes in MMD ISCH#6 iPSCs cultures and in another MMD ISCH hiPSC clone (#31) derived from the same patient at passages 0 and 10. Lack of the Sendai virus genome maintenance is shown in passage 10 cultures. Commercial hiPSCs were used as positive control for pluripotency-associated genes. **C:** Western blot analysis showing protein expression levels of pluripotency-associated markers in MMD ISCH#6 iPSCs and in other clones derived from the same patient.

(OCT4, SOX2, KLF4, and c-Myc; Takahashi et al., 2007). Colonies with typical iPSC-like morphology appeared 10–12 d after transduction and some of them were picked 16–18 d later. Clones were expanded and further characterized. One of the isolated clones gave rise to the MMD ISCH#6 iPSC line, characterized by homogeneous colonies, normal diploid 46, XX karyotype, without detectable abnormalities, and stable expression of the pluripotency markers OCT4, Nanog, SOX2 and TRA-1-60, verified by both immunofluorescence, RT-PCR and western blot (Fig. 1A–C) (Itskovitz-Eldor et al., 2000; Carpenter et al., 2003). Absence of residual episomal Sendai virus was confirmed at passage 10 (Fusaki et al., 2009), suggesting that the expression of OCT4, SOX2, KLF4, and c-Myc was indicative of a successful complete reprogramming process (Fig. 1B).

Differentiation potential of the MMD ISCH#6 iPSC line was assessed by Embryoid Body assay. Differentiated 14-day old cultures exhibited the presence of β 3-Tubulin (ectoderm), α -SMA (mesoderm) and TROMA-1 (endoderm) immunopositive cells (Fig. 2A), thus confirming the pluripotent nature of the cells (Itskovitz-Eldor et al., 2000; Carpenter et al., 2003). The differentiation competency of this cell line was equivalent to that observed for a commercial hiPSC line, as shown by the comparable expression levels of the 3 germ layers markers FGF5 (ectoderm), Nestin (neuro-ectoderm), T-Brachyury (mesoderm), SOX-17 (endoderm) assessed by qRT-PCR (Fig. 2B).

2. Materials and methods

2.1. PBMCs collection and freezing

Patient's PBMCs were isolated in BD Vacutainer CPT Cell Preparation tubes and separated by centrifugation (30 min, 1800g at room temperature). They were collected in 35 mL of PBS, centrifuged at 300g for 15 min at room temperature. Stocks of 2×10^6 cells were cryopreserved in fetal bovine serum (FBS) with 10% DMSO.

2.2. PBMCs thawing and reprogramming with Sendai virus particles

Cells were thawed in a well of a 24 well-plate and cultured in the PBMC expansion medium, composed by StemPro-34 Serum Free Medium Basal Medium (Thermo Fisher Scientific), StemPro-34 Nutrient Supplement, 200 mM GlutaMAX (Thermo Fisher Scientific), 1% Penicillin/Streptomycin (Thermo Fisher Scientific), 100 ng/mL Stem Cell Factor (SCF, Preprotech), 100 ng/mL FLT-3 (Thermo Fisher Scientific), 20 ng/mL Interleukin-6 (IL-6) (Thermo Fisher Scientific), 20 ng/mL Interleukin-3 (IL-3) (Thermo Fisher Scientific). The medium was replaced daily for 3 d.

Four days later, viral particles provided with the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific) were used to




Fig. 2. *In vitro* differentiation of MMD ISCH#6 iPSC line. **A:** Picture of Embryoid Body after 4 d of suspension culture (5 \times). At D14 cultures expressed ectodermal (β 3-Tubulin), mesodermal (α -SMA) and endodermal (TROMA-1) germ layer markers (20 \times). **B:** qRT-PCR showing a comparable expression levels of transcripts for the 3 germ-layers, FGF5 (ectoderm), Nestin (neuro-ectoderm), T-Brachyury (mesoderm) and SOX-17 (endoderm) between 14 d differentiated MMD ISCH#6 iPSCs and differentiated reference commercial hiPSCs.

Table 1

List of primers sequences, amplicons size and number of PCR cycles.

Gene	Primers sequence	Amplicon size	Cycles (PCR)
β Actin	Fw: GACAGGATGCAGAAGGAGATTACTG; Rev: CTCAGGAGGAGCAATGATCTTGTGAT	72 bp	25
OCT4	Fw: GGAAGGAATTGGGAACACAAAGG; Rev: AACTTCACCTTCCCTCAACCA	71 bp	30
SOX2	Fw: GCTACAGCATGATGCAGGACCA; Rev: TCTGCGAGCTGGTCATGGAGTT	135 bp	30
c-Myc	Fw: CCTGGTCTCCATGAGGAGAC; Rev: CAGACTCTGACCTTTTGCCAGG	128 bp	30
KLF4	Fw: CATCTCAAGGCACACCTGCGAA; Rev: TCGGTCCGATTTTGGCACTGG	156 bp	30
Nanog	Fw: CCTGTGATTTGTTGGGCTG; Rev: GACAGTCTCCGTGTGAGGCAT	78 bp	30
SeV	Fw: GGATCACTAGGTGATATCGAGC; Rev: ACCAGACAAGAGTTTAAGAGATATGTATC	181 bp	40
Nestin	Fw: GGAGAAGGACCAAGAAGT; Rev: ACCTCTCTGTGGCATTTC	153 bp	qRT-PCR
T-Brachyury	Fw: CCTTCAGCAAAGTCAAGCTCAC; Rev: TGAAGTGGGTCTCAGGGAAGCA	153 bp	qRT-PCR
FGF5	Fw: GGATACGAGGAGTTTTCAGCAAC; Rev: CTCCTGAAGTTCAGCAGTCTG	99 bp	qRT-PCR
AFP	Fw: GCAGAGGAGATGTGCTGGATTG; Rev: CGTGTCAGTTTGACGACATTCTG	113 bp	qRT-PCR
β 3-Tubulin	Fw: TCAGCGTCTACTACAACGAGGC; Rev: GCCTGAAGAGATGTCCAAAGGC	120 bp	qRT-PCR
GAPDH	Fw: CCACTCTCCACCTTTGAC; Rev: ACCCTGTTGCTGTAGCCA	102 bp	qRT-PCR

transduce Yamanaka's factors into the PBMCs in feeder-free conditions, following the manufacturer's instructions. 16–18 d post-infection, colonies with iPSC-like phenotype were identified, picked and transferred into Geltrex-coated wells and fed Essential 8 medium (E8 medium; Thermo Fisher Scientific), following the manufacturer's instruction. Self-renewing MMD ISCH#6 iPSC line and commercial hiPSC line (GIBCO, Thermo Fisher Scientific) were routinely cultured in E8 medium, with daily medium change. Cells were passaged every 3–4 d with EDTA-based dissociation solution.

2.3. In vitro differentiation

hiPSCs were collected and dissociated in order to obtain cell clumps, then plated in low attachment wells in 2 mL of conditioned medium (E8 medium) and 2 mL of fresh E8 medium supplemented with 2 mg/mL of PVA (polyvinyl alcohol, Santa Cruz Biotechnology) and 10 μ g/mL of Y-27632 ROCK inhibitor (Tebu-BIO). Two days after, cell clumps were resuspended in 4 mL of 1:1 mix composed of Essential 6 medium (E6 medium, Thermo Fisher Scientific) and E8 medium supplemented with 2 mg/mL of PVA. From the subsequent day until the end of the experiment cultures were maintained in E6 medium. At day 7, established embryoid bodies (EBs) were collected and transferred on Geltrex-coated wells, and let to differentiate for further 7 d.

2.4. RNA isolation, polymerase chain reaction (PCR) and quantitative-PCR (qPCR)

RNA was purified with the TRIzol Reagent (Thermo Fisher Scientific) following the manufacturer's protocol. cDNA was obtained by reverse-transcription with iScript cDNA Synthesis Kit (BioRad) and used to verify the expression of specific genes by RT-PCR (primers reported in Table 1). qRT-PCR (quantitative RT-PCR) was performed using SoAdvanced Universal SYBR Green Supermix Kit (BioRad), following

the recommended protocol. Data were analyzed according to the comparative $\Delta\Delta$ Ct method and normalized by using GAPDH housekeeping gene.

2.5. Immunofluorescence analysis

Cells were fixed in PFA 4% for 15 min at room temperature, permeabilized with Triton 0.3% for 10 min at room temperature, and incubated in blocking solution (FBS 5%, Triton 0.3% in PBS) for 1 h. Incubation with the primary antibodies was performed overnight at 4 °C in FBS 2%, Triton 0.2% with the antibodies reported in the Table 2. The signal was revealed with the appropriate secondary antibodies (Table 2). Nuclei were counterstained with Hoechst 33,258 (1 μ g/mL; Thermo Fisher Scientific). Pictures were detected with the microscope Leica DM IL Led Fluo and acquired with the camera Leica DFC450 C (Leica Microsystem).

2.6. Western blot assay

Cells were lysed in RIPA buffer and 20 μ g of total lysate were fractionated on 8% SDS-polyacrylamide gel, blotted onto PVDF membranes using the TransBlot Turbo apparatus (BioRad) and hybridized overnight at 4 °C with the primary antibodies reported in the Table 2. The signal was detected with appropriate HRP-conjugated secondary antibodies (BioRad) and ECL Clarity system (BioRad), using the chamber UVITECH Cambridge (Uvitech).

2.7. Karyotyping

Cell cultures were treated with 10 ng/mL colcemid (Gibco KaryoMAX Colcemid solution in PBS, Thermo Fisher Scientific) for 16 h (overnight) at 37 °C. Metaphases were collected according to standard protocols: briefly, PBS washed cells were treated with hypotonic solution (0.075 M KCl for 15 min at room temperature), fixed in acetic

Table 2

List of the antibodies used in for immunocytochemistry (IC) and Western blot (WB) assays, working dilution and species in which they are produced.

Antibody	Company	Dilution	Species
TRA 1-60	Santa Cruz Biotech	1:1000 (WB) 1:200 (IC)	Mouse IgM
Nanog	Santa Cruz Biotech	1:1000 (WB) 1:100 (IC)	Mouse
SOX2	Millipore	1:2000 (WB) 1:300 (IC)	Rabbit
OCT4	Santa Cruz Biotech	1:1000 (WB) 1:100 (IC)	Rabbit
α -SMA	Sigma	1:1000 (IC)	Mouse
TROMA-1	Iowa DHB	1:100 (IC)	Mouse
β 3-Tubulin	Promega	1:1000 (IC)	Mouse
Anti-rabbit HRP	BioRad	1:3000	Goat
Anti-mouse HRP	BioRad	1:3000	Goat
Anti-mouse IgM FITC	Santa Cruz Biotech	1:200	Goat
Alexa Fluor IgG anti-rabbit 568	Life Technologies	1:300	Goat
Alexa Fluor IgG anti-rabbit 488	Life Technologies	1:300	Goat
Alexa Fluor IgG anti-mouse 568	Life Technologies	1:300	Goat
Alexa Fluor IgG anti-mouse 488	Life Technologies	1:300	Goat

acid/methanol (1:3 v/v) and air-dried metaphase spreads slides were analyzed by QFQ banding. Microscope observation was performed using a Nikon Eclipse 90i (Nikon Instruments) equipped with the acquisition and analysis Genikon software (Nikon Instruments).

Acknowledgements

We are grateful to Giusi Rossi, all volunteers of Associazione Amici del Moyamoya and the families of the patients suffering from MMD for their trust and affection. A particular obligation to Monica Rossi and MMD patients for their vivid example of firmness, support and generosity. This study was supported by funding from Associazione Amici del Moyamoya ONLUS (40102525) (<http://amicidelmoyamoya.org/it>; Italy).

References

- Carpenter, M.K., Rosler, E., Rao, M.S., 2003. Characterization and differentiation of human embryonic stem cells. *Cloning Stem Cells* 5 (1), 79–88.
- Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M., 2009. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* 85 (8), 348–362.
- Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D., Eden, A., Yanuka, O., Amit, M., Soreq, H., Benvenisty, N., 2000. Differentiation of human embryonic stem cells into embryoid bodies compromising the three embryonic germ layers. *Mol. Med.* 6 (2), 88–95.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131 (5), 861–872.
- Yang, W., Mills, J.A., Sullivan, S., Liu, Y., French, D.L., Gadue, P., 2008–2012. iPSC reprogramming from human peripheral blood using sendai virus mediated gene transfer. *StemBook* [Internet]. Harvard Stem Cell Institute, Cambridge (MA) .